Blog

Contains articles from Dante and our partners discussing the latest research, publications, and updates about genome sequencing.
Genomic Biopharma Inc logo
About Us

Dante Genomics creates separate drug discovery and development company Genomic Biopharma Inc.

Dante Genomics, a global leader in genomics and precision medicine, is pleased to announce that the Company’s co-founder and CEO Andrea Riposati presented as an opening speaker on Tuesday, September 27, 2022 at the 77th United Nations General Assembly (UNGA) Science Summit, where he unveiled the Company’s Digital Health Population Genomics Program in Europe, including living labs, which are groundbreaking pilot studies with fast impact on a country’s society and digital health.

Read More ➝
About Us

Dante Genomics Unveils Digital Health Population Genomics Program at the United Nations General Assembly Science Summit

 Dante Genomics, a global leader in genomics and precision medicine, is pleased to announce that the Company’s co-founder and CEO Andrea Riposati presented as an opening speaker on Tuesday, September 27, 2022 at the 77th United Nations General Assembly (UNGA) Science Summit, where he unveiled the Company’s Digital Health Population Genomics Program in Europe, including living labs, which are groundbreaking pilot studies with fast impact on a country’s society and digital health.

Read More ➝
image angela patient
Genome Sequencing

Angela’s Story

Angela was in her early 20s when she came to Dante Labs desperate for help in diagnosing her strange symptoms. Dante Labs sequenced Angela’s whole genome ultimately diagnosing Angela with a rare disease, bringing her out of a years long diagnostic odyssey.

Read More ➝
image partnership
Diagnostics

Dante Labs Partnering with The Renato Dulbecco Foundation to advance personalized medicines for cancer, COVID-19 and rare diseases

Dante Labs, a global leader in genomics and precision medicine, today announced it has partnered with The Renato Dulbecco Foundation to deliver more personalized therapies in rare diseases, oncology and COVID-19. Protelica, the groundbreaking US biotechnology company, has licensed its library of billions of pronectines nanoantibodies and a portfolio of 12 patents to The Renato Dulbecco Foundation.

Read More ➝